DarioHealth Corp. (DRIO) |
| 6.77 -0.044 (-0.65%) 07-20 16:00 |
| Open: | 6.07 |
| High: | 6.8 |
| Low: | 6.07 |
| Volume: | 13,010 |
| Market Cap: | 50(M) |
| PE Ratio: | -1.16 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 8.00 |
| Resistance 1: | 7.18 |
| Pivot price: | 6.90 |
| Support 1: | 5.84 |
| Support 2: | 4.86 |
| 52w High: | 17.744 |
| 52w Low: | 5.845 |
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
| EPS | -8.500 |
| Book Value | 8.550 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.773 |
| Profit Margin (%) | -192.23 |
| Operating Margin (%) | -130.89 |
| Return on Assets (ttm) | -19.7 |
| Return on Equity (ttm) | -59.9 |
Thu, 16 Jul 2026
Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform - PR Newswire
Wed, 15 Jul 2026
DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients - Streetwise Reports
Wed, 15 Jul 2026
DarioHealth (DRIO) Corporate presentation Summary - Quartr
Sat, 11 Jul 2026
DarioHealth (DRIO) Q1 2026 earnings summary - Quartr
Thu, 09 Jul 2026
Enterprise value to EBIT forward of DarioHealth Corp. – NASDAQ:DRIO - TradingView
Wed, 08 Jul 2026
DarioHealth (DRIO) Secures Arizona Insurer Deal via Amwell - Streetwise Reports
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |